BCR and chronic myelogenous leukemia, BCR-ABL1 positive: We compared the effect of DAS-IAP and DAS-meIAP on CML cell growth, and found that growth suppression by short-term treatment with DAS-IAP is due to degradation of BCR-ABL and not to the inhibition of BCR-ABL kinase activity.